As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Featured Review: Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
Jatin Machhi, …, Howard E. Gendelman
Featured Review: From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline
Rajka Maria Liscic, …, Emanuele Buratti
It is with regret we announce the cancellation of the 6th International Conference on Molecular Neurodegeneration, due to the unstable situation and travel restrictions surrounding the novel Coronavirus.
Please see the ICMN website for further details.
Parkinson's disease - a series of reviews
Molecular Neurodegeneration presents a new thematic series, collating reviews on recent advances in Parkinson's Disease research.
Guest Edited by Mark Cookson and Ted Dawson, reviews will continue to publish throughout 2020. The collection can be read here.
The leading open access journal in the field of neurosciences, Molecular Neurodegeneration encompasses all aspects of neurodegeneration research at the molecular and cellular levels.
- Guojun Bu, Mayo Clinic, USA
- Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA
Molecular Neurodegeneration is the official journal of the BrightFocus Foundation.
Guojun Bu, Mayo Clinic, USA
Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA
Annual Journal Metrics
43 days to first decision for reviewed manuscripts only
20 days to first decision for all manuscripts
121 days from submission to acceptance
23 days from acceptance to publication
570 Altmetric mentions